Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Biospecimens and biorepositories for the community pathologist.

Dash RC, Robb JA, Booker DL, Foo WC, Witte DL, Bry L.

Arch Pathol Lab Med. 2012 Jun;136(6):668-78. doi: 10.5858/arpa.2011-0274-SO.

2.

A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study.

Steele BW, Wang E, Soldin SJ, Klee G, Elin RJ, Witte DL; College of American Pathologists Study.

Arch Pathol Lab Med. 2003 Mar;127(3):283-8.

PMID:
12653570
3.

Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study.

Soldin SJ, Steele BW, Witte DL, Wang E, Elin RJ; College of American Pathologists Study.

Arch Pathol Lab Med. 2003 Jan;127(1):19-22.

PMID:
12521361
4.

An evaluation of analytic goals for assays of drugs: a College of American Pathologists Therapeutic Drug Monitoring Survey Study.

Steele BW, Wang E, Palomaki GE, Klee GG, Elin RJ, Soldin SJ, Witte DL.

Arch Pathol Lab Med. 2001 Jun;125(6):729-35.

PMID:
11371222
5.

Sources of variability: a College of American Pathologists Therapeutic Drug Monitoring study.

Steele BW, Wang E, Palomaki G, Klee GG, Elin RJ, Witte DL.

Arch Pathol Lab Med. 2001 Feb;125(2):183-90.

PMID:
11175632
6.
7.

Frequency of unacceptable results in point-of-care testing.

Witte DL, VanNess SA.

Arch Pathol Lab Med. 1999 Sep;123(9):761. No abstract available.

PMID:
10458818
8.

Strategies to increase detection of hemochromatosis.

McDonnell SM, Witte DL, Cogswell ME, McIntyre R.

Ann Intern Med. 1998 Dec 1;129(11):987-92. Review.

PMID:
9867752
9.

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.

Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL.

Arch Pathol Lab Med. 1998 Sep;122(9):782-98. Review.

PMID:
9740136
10.
11.

Errors, mistakes, blunders, outliers, or unacceptable results: how many?

Witte DL, VanNess SA, Angstadt DS, Pennell BJ.

Clin Chem. 1997 Aug;43(8 Pt 1):1352-6.

12.

Mild liver enzyme abnormalities: eliminating hemochromatosis as cause.

Witte DL.

Clin Chem. 1997 Aug;43(8 Pt 2):1535-8. Review.

13.

Panel discussion: how to monitor and minimize variation and mistakes.

Witte DL, Astion ML.

Clin Chem. 1997 May;43(5):880-5. No abstract available.

14.

Quality for tomorrow: by design or by checking?

Garber CC, Witte DL.

Clin Chem. 1997 May;43(5):864-5. No abstract available.

15.
16.

Computer software programs and Down's syndrome risk calculations.

Knight GJ, Haddow JE, Palomaki GE, Donhowe JM, Witte DL.

Lancet. 1996 Jun 1;347(9014):1553. No abstract available.

PMID:
8684123
17.

Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis.

Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA.

Clin Chim Acta. 1996 Feb 28;245(2):139-200. Review.

PMID:
8867884
18.

Measuring outcomes: why now?

Witte DL.

Clin Chem. 1995 May;41(5):775-80. Review.

19.

Serum iron: would analytical improvement enhance patient outcome?

Eckfeldt JH, Witte DL.

Clin Chem. 1994 Apr;40(4):505-7. Review. No abstract available.

20.
21.

Wellness testing. Design and experience of an established program.

Witte DL.

Clin Lab Med. 1993 Jun;13(2):481-90. Review.

PMID:
8319431
22.
24.

The use of mortality studies in underwriting malignancies.

Kay BR, Witte DL.

J Insur Med. 1991 Fall;23(3):185-8. No abstract available.

PMID:
10148502
25.
26.

The impact of cancer biology, lead time bias, and length bias in the debate about cancer screening tests.

Kay BR, Witte DL.

J Insur Med. 1991 Summer;23(2):102-4. No abstract available.

PMID:
10147769
27.

Hemochromatosis 1991. What will increased clinical screening mean for medical directors?

Witte DL, Kay BR.

J Insur Med. 1991 Winter;23(4):281-3. Review. No abstract available.

PMID:
10147832
28.

Can serum ferritin be effectively interpreted in the presence of the acute-phase response?

Witte DL.

Clin Chem. 1991 Apr;37(4):484-5. No abstract available.

29.

Chemistry profiles in "wellness programs": test selection and participant outcomes.

Witte DL, Angstadt DS, Schweitzer JK.

Clin Chem. 1988 Jul;34(7):1447-50.

30.

Predicting bone marrow iron stores in anemic patients in a community hospital using ferritin and erythrocyte sedimentation rate.

Witte DL, Angstadt DS, Davis SH, Schrantz RD.

Am J Clin Pathol. 1988 Jul;90(1):85-7.

PMID:
3389347
31.

Prediction of bone marrow iron findings from tests performed on peripheral blood.

Witte DL, Kraemer DF, Johnson GF, Dick FR, Hamilton H.

Am J Clin Pathol. 1986 Feb;85(2):202-6.

PMID:
3946303
32.

Serum 5'-nucleotidase in patients receiving anti-epileptic drugs.

Fortman CS, Witte DL.

Am J Clin Pathol. 1985 Aug;84(2):197-201.

PMID:
2862788
33.

Successful cardiac surgery following plasmapheresis in a patient with hemophilia B.

Raish RJ, Witte DL, Goldsmith JC.

Transfusion. 1985 Mar-Apr;25(2):128-30.

PMID:
3872488
34.

Single-stage automated assay for heparin.

Kapke GF, Feld RD, Witte DL, Johnson GF.

Clin Chem. 1982 Jul;28(7):1521-4.

35.

Use of alpha cyclodextrin to eliminate interference by nonesterified fatty acids in calcium measurements.

Witte DL, Pennell BJ, Pfohl JK, Feld RD.

Am J Clin Pathol. 1981 Jul;76(1):86-8.

PMID:
7258156
36.

Esterolytic method for determination of heparin in plasma.

Kapke GF, Feld RD, Witte DL, Owen WG.

Clin Chem. 1981 Apr;27(4):526-9.

37.
38.

Enzymic inhibition assay for methotrexate with a discrete analyzer, the ABA-100.

Brown LF, Johnson GF, Witte DL, Feld RD.

Clin Chem. 1980 Feb;26(2):335-8.

39.

The presence of creatine kinase BB isoenzyme in patients with prostatic cancer.

Feld RD, van Steirteghem AC, Zweig MH, Weimar GW, Narayana AS, Witte DL.

Clin Chim Acta. 1980 Jan 31;100(3):267-73.

PMID:
7353312
40.

Platelet and leukocyte counts in pregnancy.

Pitkin RM, Witte DL.

JAMA. 1979 Dec 14;242(24):2696-8.

PMID:
501868
41.
42.

Comparison of dewpoint and freezing point osmometry.

Mercier DE, Feld RD, Witte DL.

Am J Med Technol. 1978 Nov;44(11):1066-9.

PMID:
717430
43.
44.

Effects of bilirubin on detection of hydrogen peroxide by use of peroxidase.

Witte DL, Brown LF, Feld RD.

Clin Chem. 1978 Oct;24(10):1778-82.

45.

Serum uric acid determined by reversed-phase liquid chromatography with spectrophotometric detection.

Kiser EJ, Johnson GF, Witte DL.

Clin Chem. 1978 Apr;24(4):536-40. No abstract available.

46.
47.

Evaluation of a glucose oxidase procedure.

Putz GR, Barrett DA 2nd, Witte DL.

Am J Med Technol. 1976 Oct;42(10):351-6.

PMID:
824952
48.

Letter: Is Dextrostix adequate to assess neonatal hypoglycemia?

Barrett DA 2nd, Witte DL, Brown L.

J Pediatr. 1976 Jun;88(6):1072. No abstract available.

PMID:
1271186
49.

The effects of therapy for mild hypertension on circulating level of dopamine beta-hydroxylase.

Grant C, Routh JI, Lawton W, Witte DL.

Clin Chim Acta. 1976 Jun 1;69(2):333-40.

PMID:
1277563
50.

The anion gap: its use in quality control.

Witte DL, Rodgers JL, Barrett DA 2nd.

Clin Chem. 1976 May;22(5):643-6.

PMID:
1261013

Supplemental Content

Loading ...
Support Center